From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
  • 21378331
Chemical and physical data
Formula C24H23Cl3N2
Molar mass 445.811 g·mol−1
3D model (JSmol)
  • Interactive image

VCHSR is a drug used in scientific research which acts as a selective antagonist of the cannabinoid receptor CB1. It is derived from the widely used CB1 antagonist rimonabant, and has similar potency and selectivity for the CB1 receptor, but has been modified to remove the hydrogen bonding capability in the C-3 substituent region, which removes the inverse agonist effect that rimonabant produces at high doses, so that VCHSR instead acts as a neutral antagonist, blocking the receptor but producing no physiological effect of its own.[1][2]


  1. ^ Hurst, DP; Lynch, DL; Barnett-Norris, J; Hyatt, SM; Seltzman, HH; Zhong, M; Song, ZH; Nie, J; et al. (2002). "N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor". Molecular Pharmacology. 62 (6): 1274–87. doi:10.1124/mol.62.6.1274. PMID 12435794.
  2. ^ Hurst, D; Umejiego, U; Lynch, D; Seltzman, H; Hyatt, S; Roche, M; McAllister, S; Fleischer, D; et al. (2006). "Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction". Journal of Medicinal Chemistry. 49 (20): 5969–87. doi:10.1021/jm060446b. PMID 17004712.

Retrieved from ""
This content was retrieved from Wikipedia :
This page is based on the copyrighted Wikipedia article "VCHSR"; it is used under the Creative Commons Attribution-ShareAlike 3.0 Unported License (CC-BY-SA). You may redistribute it, verbatim or modified, providing that you comply with the terms of the CC-BY-SA